- Amgen can be a cornerstone in your portfolio due to its fortress financial strength, secular support, and strong profitability.
- At its present price levels, a dividend discount reveals a very asymmetric return profile with an upside near 40% but little downside.
- Its Accelerated Stock Repurchase (ASR) agreement of up to $6 billion and healthy dividends add another layer of safety to the investment.
- Strong pipeline, biosimilars, and collaboration with Eli Lilly to develop COVID-19 antibody add further upside catalysts.
For further details see:
Amgen: Safe Harbor In Turbulent Times